TKNO · Alpha Teknova, Inc.

Alpha Teknova delivered a strong start to 2026 with Q1 total revenue of $11.1 million, a 13% increase from $9.8 million in the prior year quarter, driven primarily by an 85% surge in Clinical Solutions revenue to $2.1 million as customers advance therapies and diagnostics toward commercialization. Lab Essentials revenue grew modestly 3% to $8.4 million. Gross profit rose to $3.8 million with margin expansion to 34.2% from 30.7%, attributed to higher revenue volumes. Operating expenses edged up to $8.1 million, reflecting increased sales and marketing investments from higher headcount and marketing spend, offset by lower G&A due to reduced stock-based compensation and professional fees. Net loss remained stable at $4.6 million or ($0.08) per diluted share, supported by 53.6 million weighted average shares. Adjusted EBITDA improved to negative $2.0 million from negative $2.5 million. Cash used in operations improved to $3.4 million from $4.1 million, with Free Cash Outflow at $3.6 million. Balance sheet shows $17.8 million in cash and short-term investments against $13.2 million borrowings as of March 31, 2026. Management, led by CEO Stephen Gunstream and CFO Matt Lowell, highlights investments since 2021 and improved market conditions positioning for sustainable growth, reaffirming full-year revenue guidance of $42-44 million and Free Cash Outflow below $10 million. Separately, the Board approved non-substantive amendments to the Code of Business Conduct and Ethics on May 4, 2026, to update compliance practices and streamline provisions, available on the company's website.